| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Akari Therapeutics Plc | Interim CFO | American Depositary Shares representing Ordinary Shares | 26,619 | $19,964 | $0.7500 | 01 Nov 2025 | Direct |
| Akari Therapeutics Plc | Interim CFO | Pre-Funded Warrants to purchase ADRs | 24,745 | $9,999 | $0.4041 | 16 Dec 2025 | Direct |
| BIOVIE INC. | Director | Stock Option (right to buy) | 57,500 | 05 Jan 2026 | Direct | ||
| Akari Therapeutics Plc | Interim CFO | Warrants to purchase American Depositary Shares ("ADRs") | 24,745 | 16 Dec 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| BIVI | BIOVIE INC. | 05 Jan 2026 | 1 | $0 | 4 | Director | 09 Jan 2026, 17:01 |
| AKTX | Akari Therapeutics Plc | 16 Dec 2025 | 2 | +$9,999 | 4 | Interim CFO | 18 Dec 2025, 21:57 |
| AKTX | Akari Therapeutics Plc | 01 Nov 2025 | 2 | +$43,964 | 4 | Interim CFO | 04 Nov 2025, 17:00 |
| AKTX | Akari Therapeutics Plc | 22 Oct 2025 | 1 | +$4,645 | 4 | Interim CFO | 24 Oct 2025, 09:18 |
| AKTX | Akari Therapeutics Plc | 22 Oct 2025 | 0 | $0 | 3 | Interim CFO | 24 Oct 2025, 09:15 |
| BIVI | BIOVIE INC. | 17 Jul 2025 | 0 | $0 | 3 | Director | 28 Oct 2025, 11:20 |